SymBio Pharmaceuticals Limited (4582.T)
JPY 158.0
(0.64%)
JPY 158.0
(0.64%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 4.41 Billion JPY | -41.96% |
| 2022 | 7.59 Billion JPY | 31.03% |
| 2021 | 5.8 Billion JPY | 569.1% |
| 2020 | 866.85 Million JPY | 0.24% |
| 2019 | 864.75 Million JPY | -26.27% |
| 2018 | 1.17 Billion JPY | 13.73% |
| 2017 | 1.03 Billion JPY | 14.05% |
| 2016 | 904.19 Million JPY | 55.09% |
| 2015 | 582.99 Million JPY | 10.7% |
| 2014 | 526.63 Million JPY | 65.61% |
| 2013 | 317.99 Million JPY | -46.37% |
| 2012 | 592.97 Million JPY | -9.93% |
| 2011 | 658.33 Million JPY | -45.67% |
| 2010 | 1.21 Billion JPY | 1.73% |
| 2009 | 1.19 Billion JPY | -26.93% |
| 2008 | 1.63 Billion JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 471.1 Million JPY | -49.6% |
| 2024 Q3 | 448.06 Million JPY | -14.68% |
| 2024 Q2 | 525.16 Million JPY | 11.48% |
| 2023 Q4 | 934.76 Million JPY | -6.82% |
| 2023 Q1 | 1.24 Billion JPY | -41.72% |
| 2023 FY | 4.41 Billion JPY | -41.96% |
| 2023 Q2 | 1.22 Billion JPY | -1.08% |
| 2023 Q3 | 1 Billion JPY | -18.43% |
| 2022 Q4 | 2.13 Billion JPY | 46.5% |
| 2022 FY | 7.59 Billion JPY | 31.03% |
| 2022 Q1 | 1.89 Billion JPY | 8.2% |
| 2022 Q2 | 2.11 Billion JPY | 11.29% |
| 2022 Q3 | 1.45 Billion JPY | -31.06% |
| 2021 Q3 | 1.77 Billion JPY | 40.03% |
| 2021 Q1 | 1 Billion JPY | 294.38% |
| 2021 FY | 5.8 Billion JPY | 569.1% |
| 2021 Q4 | 1.75 Billion JPY | -0.95% |
| 2021 Q2 | 1.26 Billion JPY | 25.23% |
| 2020 FY | 866.85 Million JPY | 0.24% |
| 2020 Q2 | 202.19 Million JPY | 58.34% |
| 2020 Q1 | 127.7 Million JPY | -57.69% |
| 2020 Q3 | 280.86 Million JPY | 38.9% |
| 2020 Q4 | 256.09 Million JPY | -8.82% |
| 2019 Q3 | 33.49 Million JPY | 142.14% |
| 2019 Q2 | -79.48 Million JPY | -113.05% |
| 2019 FY | 864.75 Million JPY | -26.27% |
| 2019 Q4 | 301.85 Million JPY | 801.1% |
| 2019 Q1 | 608.89 Million JPY | 144.89% |
| 2018 Q4 | 248.64 Million JPY | -29.15% |
| 2018 FY | 1.17 Billion JPY | 13.73% |
| 2018 Q1 | 249.5 Million JPY | -30.03% |
| 2018 Q2 | 323.79 Million JPY | 29.78% |
| 2018 Q3 | 350.92 Million JPY | 8.38% |
| 2017 Q3 | 164.77 Million JPY | -39.17% |
| 2017 FY | 1.03 Billion JPY | 14.05% |
| 2017 Q1 | 239.01 Million JPY | -43.86% |
| 2017 Q2 | 270.88 Million JPY | 13.33% |
| 2017 Q4 | 356.59 Million JPY | 116.41% |
| 2016 FY | 904.19 Million JPY | 55.09% |
| 2016 Q4 | 425.77 Million JPY | 478.29% |
| 2016 Q1 | 56.5 Million JPY | -69.93% |
| 2016 Q2 | 348.28 Million JPY | 516.36% |
| 2016 Q3 | 73.62 Million JPY | -78.86% |
| 2015 Q1 | 120.41 Million JPY | -30.46% |
| 2015 Q3 | 112.5 Million JPY | -30.63% |
| 2015 FY | 582.99 Million JPY | 10.7% |
| 2015 Q4 | 187.9 Million JPY | 67.02% |
| 2015 Q2 | 162.16 Million JPY | 34.67% |
| 2014 Q3 | 106.35 Million JPY | -50.48% |
| 2014 FY | 526.63 Million JPY | 65.61% |
| 2014 Q4 | 173.15 Million JPY | 62.8% |
| 2014 Q2 | 214.77 Million JPY | 563.71% |
| 2014 Q1 | 32.35 Million JPY | -27.84% |
| 2013 Q2 | 33.37 Million JPY | -77.9% |
| 2013 Q3 | 88.79 Million JPY | 166.08% |
| 2013 Q4 | 44.84 Million JPY | -49.5% |
| 2013 FY | 317.99 Million JPY | -46.37% |
| 2013 Q1 | 150.98 Million JPY | 39.67% |
| 2012 Q3 | 219.37 Million JPY | 60.03% |
| 2012 Q4 | 108.1 Million JPY | -50.72% |
| 2012 FY | 592.97 Million JPY | -9.93% |
| 2012 Q1 | 128.41 Million JPY | -47.15% |
| 2012 Q2 | 137.08 Million JPY | 6.76% |
| 2011 Q1 | 83.17 Million JPY | 0.0% |
| 2011 Q2 | 252.67 Million JPY | 203.78% |
| 2011 Q3 | 79.49 Million JPY | -68.54% |
| 2011 Q4 | 242.99 Million JPY | 205.67% |
| 2011 FY | 658.33 Million JPY | -45.67% |
| 2010 Q4 | - JPY | 0.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 FY | 1.21 Billion JPY | 1.73% |
| 2009 Q4 | - JPY | 0.0% |
| 2009 FY | 1.19 Billion JPY | -26.93% |
| 2008 FY | 1.63 Billion JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 48.75 Billion JPY | 90.952% |
| Takeda Pharmaceutical Company Limited | 2184.96 Billion JPY | 99.798% |
| Sumitomo Pharma Co., Ltd. | 187.98 Billion JPY | 97.653% |
| Shionogi & Co., Ltd. | 369.08 Billion JPY | 98.805% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.54 Billion JPY | -24.575% |
| Nippon Shinyaku Co., Ltd. | 97.01 Billion JPY | 95.453% |
| Kaken Pharmaceutical Co., Ltd. | 38.22 Billion JPY | 88.459% |
| Eisai Co., Ltd. | 586.41 Billion JPY | 99.248% |
| Morishita Jintan Co., Ltd. | 5.99 Billion JPY | 26.459% |
| Hisamitsu Pharmaceutical Co., Inc. | 78.97 Billion JPY | 94.414% |
| Mochida Pharmaceutical Co., Ltd. | 52.07 Billion JPY | 91.529% |
| Fuso Pharmaceutical Industries,Ltd. | 13.51 Billion JPY | 67.367% |
| Nippon Chemiphar Co., Ltd. | 7.73 Billion JPY | 42.995% |
| Tsumura & Co. | 68.81 Billion JPY | 93.59% |
| Kissei Pharmaceutical Co., Ltd. | 37.34 Billion JPY | 88.187% |
| Torii Pharmaceutical Co., Ltd. | 24.79 Billion JPY | 82.208% |
| Towa Pharmaceutical Co., Ltd. | 81.38 Billion JPY | 94.58% |
| Fuji Pharma Co., Ltd. | 16.51 Billion JPY | 73.291% |
| Zeria Pharmaceutical Co., Ltd. | 50.18 Billion JPY | 91.21% |
| KYORIN Holdings, Inc. | 51.4 Billion JPY | 91.418% |
| Taiko Pharmaceutical Co.,Ltd. | 1.07 Billion JPY | -308.806% |
| Daito Pharmaceutical Co.,Ltd. | 9.83 Billion JPY | 55.168% |
| MedRx Co., Ltd | 26 Million JPY | -16865.438% |
| Mizuho Medy Co.,Ltd. | 8.02 Billion JPY | 45.039% |
| Solasia Pharma K.K. | 337 Million JPY | -1208.906% |
| Modalis Therapeutics Corporation | -731 Thousand JPY | 603521.888% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 30.66 Billion JPY | 85.615% |
| Sawai Group Holdings Co., Ltd. | 54.31 Billion JPY | 91.879% |
| Cyfuse Biomedical K.K. | 37.74 Million JPY | -11586.663% |
| Toho Holdings Co., Ltd. | 112.98 Billion JPY | 96.096% |
| Koa Shoji Holdings Co.,Ltd. | 6.63 Billion JPY | 33.565% |